Company ProfilePremium

Newtree S.A.

Company Profile Analysis

Ticker: NEWT.BR

ESOMAR 23 Corporate BadgeISO Certifications Badge
Newtree S.A. - Company showcase

Year Founded & Workforce

2001

5 Employees

Newtree S.A. logo

Newtree S.A. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Newtree S.A. Overview

Newtree Impact is one of the very few listed, retail-accessible vehicles in Europe that specialise in early-growth agri-food technology. It is the former Belgian functional-chocolate company NewTree, converted into an evergreen holding that takes minority stakes of roughly €0.3M to €2.5M in Series A to growth-stage companies and in specialist funds. Its themes are food-tech (alternative proteins, precision fermentation, alternative fats and cocoa), agri-tech (precision agriculture, pollination) and food loss. With about €25M of NAV, €17.5M deployed into 25 lines, no debt and about €10.8M of cash at end-2025, it is still sub-scale. Its distinguishing features are its "société à mission" status (the company says it was the first Belgian financial company to adopt it), an independent Mission Committee, IRIS+-based impact reporting and a model of citizen "crowdlisting" alongside institutional anchors (Wallonie Entreprendre, SFPIM). The investment case rests on portfolio maturation toward profitability and exits, against a backdrop of NAV per share that has slipped since 2023 and a very illiquid share.


What the company does

Newtree SA is an investment holding company. It raises equity from private investors, family offices, institutions and the public, and invests that capital as a minority shareholder in private companies and venture funds working on the agri-food system. Its stated purpose is to fight climate change by changing how food is produced, processed and consumed, while targeting market-rate financial returns.

Company's own description (paraphrased from its 2026 investor materials and website). Newtree Impact presents itself as an investment holding that pairs financial returns with environmental impact. It invests in disruptive technology companies reshaping food systems, organised around three themes: Food-Tech (ingredients and dietary shifts), Agri-Tech (agricultural innovation) and Food-Loss (waste streams and upcycling). It invests at Series A to growth stage using its own impact methodology, which is inspired by the UN Sustainable Development Goals and measured with IRIS+ metrics. The company stresses that it is a holding company and not an investment fund: it invests for its own account and says it does not primarily aim to profit from selling its participations (OGM, 2 Jun 2026; Newtree Impact Investors page).

Independent characterisation. In economic terms the vehicle works like a small, permanent-capital venture fund wrapped in a listed company. Its value lies almost entirely in unlisted minority stakes valued under IPEV guidelines; BDO built its valuation tool and policy. It carries cash on the balance sheet, earns negligible operating revenue and pays its costs (about €0.6M a year) out of capital. Shareholder returns depend on (a) uplifts in portfolio valuations, (b) eventual exits, which the company says will first clear accumulated losses and then be distributed, and (c) whether the share price trades at a premium or discount to NAV on a very thin Euronext Access order book. The legal emphasis on "holding, not fund" places it outside the Belgian and EU collective-investment rules (AIFMD) that would otherwise apply, which keeps costs low but also reduces the formal investor protections a regulated fund would offer.

Business and revenue model

Revenue / value sourceDescriptionMateriality
Unrealised valuation changesPeriodic IPEV-based re-measurement of participations, reflected in NAV but not in Belgian GAAP profit (only write-downs are booked)Main driver of NAV. Revaluations were +€1.0M (2023), −€1.4M (2024) and −€2.8M (2025) per the NAV bridge.
Realised gains on exitsSale of participationsNone disclosed to date
Interest incomeReturn on cash€95k (FY2024); €34k (FY2025)
Operating revenueMinor service and other income€5k (FY2024); €32k (FY2025)
Fees from investorsNone. The holding does not charge shareholders management fees or carried interest. Costs are borne by the company; the term sheet cites an annual cost of about 2% of total equity and no carry. The Spreds offer states costs are capped at 1.75% of NAV once NAV exceeds €25M.OGM 2026 term sheet; Spreds

Product / service / subscription / licensing mix: not applicable. The company has no product, subscription or licensing revenue at the holding level. The only operating products in the wider group sit in portfolio company Newtree Group SA (chocolate, spreads and office coffee).

Value-chain position, "customers" and end-markets

Value-chain position: a growth-stage capital provider positioned between seed and angel investors and late-stage, strategic or IPO investors. It frequently co-invests alongside specialist VCs and corporates (for example Bel Group, Danone Ventures, PINC, Big Idea Ventures, Beyond Impact).

"Customers" on the capital side: about 750 or more shareholders, comprising founders, family offices, angels, institutions (Wallonie Entreprendre, SFPIM, Noshaq, Whitestone Group, among others) and retail investors who came in through crowdlisting campaigns on Spreds and Ecco Nova (BE and FR).

"Customers" on the asset side: entrepreneurs in Food-Tech, Agri-Tech and Food-Loss.

End-markets indirectly exposed: alternative proteins (plant-based, fermentation, insect), food ingredients (fats, flavours, egg and dairy proteins, cocoa alternatives), precision agriculture, pollination and biodiversity services, aquaculture, animal health (bacteriophages), food-waste analytics, and premium consumer chocolate and coffee.

Operating model and cost base

The holding runs with five operational staff, an Investment Committee of five external members, a Mission Committee of four and a Board of seven. Operating expenses were €573k in FY2025 (salaries €462k, rent and supplies €28k, other €74k, listing fees €9k), plus €57k of depreciation (FY2025 income statement). Management puts opex at 2.3% of NAV in 2025, against 2.2% in 2024 and 2.1% in 2023 and 2022.

Strategy

Stated strategy (themes from the June 2026 OGM and website, paraphrased)

  1. Mission: invest in science-driven innovations that address the root inefficiencies of a food system the company says generates about €13 trillion a year in hidden environmental, health and social costs.

  2. Dual approach: combine direct minority stakes (Series A to growth, plus opportunistic late-stage and listed equity) with fund commitments for diversification and deal-flow visibility.

  3. No trade-off on impact: the company says it seeks to maximise environmental and financial returns together rather than merely mitigate ESG risk.

  4. Democratising impact investing: make private-market impact exposure accessible to retail investors through listing and crowdlisting.

  5. Scale targets (term sheet): €50–100M of equity, 35–40 portfolio companies, tickets of €0.5–2.5M, target IRR of 12% (term sheet) or 15% (deck "at a glance"), and a holding horizon described as indefinite but 10–15 years in practice.

Strategic initiatives (last 24 months)

InitiativeDateDescriptionStatus
Public crowdlisting (Belgium)May–Aug 2024First retail campaign; about €2M raised through Spreds and Ecco NovaCompleted
€10M capital raise with institutional anchorsDec 2025€8.7M private placement led by WE and SFPIM, plus €1.3M first cross-border BE–FR crowdlisting with 295 investorsCompleted
Société à mission status and Mission Committee2024–2025 (date n/d)Company says it is the first Belgian financial company with this statusIn place
Annual Impact Report (first edition, 2025)2,025Uses IRIS+ methodology with planetary boundaries as its frameworkPublished
Newtree Group professionalisation2,025Operating Partner J-F Cambier appointed CEO of Newtree Group; €200k tranche investedOngoing
Diversification into agri-tech and food waste2025–2026Ubees (pollination), Orbisk (food waste); stated 2026 priorityOngoing
Belgian deployment alongside institutions2,026Stated objective following WE and SFPIM entryPlanned
Secondary liquidity among registered holders2,026Organise secondary transactions to offset the thin floatPlanned
Next capital increase2,026"Upcoming capital increase planned" (OGM 2026); size and terms n/dPlanned
Investor meeting26 Nov 2026Annual investor gatheringScheduled

Medium-term targets and guidance

TargetValueSource
Target IRR15% (deck "at a glance"); 12% (term sheet); 10–15% over 10–15 years (Ecco Nova 2024)OGM 2026; Ecco Nova
Projected NAV by 2032 (no new capital)€59.5M, 2.3x, implied IRR 12.6%OGM 2026
Target equity / AUM€50–100MOGM 2026 term sheet
Target portfolio size35–40 companiesOGM 2026 term sheet
Cost cap1.75% of NAV above €25M of NAV (Spreds); about 2% of total equity (term sheet)Spreds; OGM 2026
Portfolio profitability milestonesHeura EBITDA+ Q1 2026; Fable EBITDA+ during Q2 2026; Ubees consistently positive from Q2 2026; CropX first positive quarter Q2 2026 and full year 2027OGM 2026

Formal earnings guidance: none is issued.

Products & Services

For an investment holding, the "product" is the portfolio. Section 5.1 catalogues every disclosed participation. Section 5.2 catalogues the consumer products of portfolio company Newtree Group, which continue the original NewTree brand.

Investment portfolio (all disclosed lines)

#Company / fundCountryThemeWhat it doesNewtree ticketInvestee capital raisedFirst investedCEO / lead
1Newtree Group SABEFood-TechPremium organic, Fairtrade, carbon-neutral chocolate and coffee brand; described as a climate-friendly food platform€2,250,000Spin-off2,021Benoît de Bruyn & G. de Walque (site); J-F Cambier CEO (2025)
2Heura FoodsESFood-TechPlant-based meat brand rooted in Mediterranean food culture; reached positive EBITDA in Q1 2026€1,750,000€4.9M (site); a €40M round in Feb 2024 was linked to an Upfield alliance2,023Marc Coloma
3Aqua-SparkNLAgri-Tech (fund / coop)Evergreen fund investing across the sustainable aquaculture value chain€1,200,000AUM €294M2,020Amy Novogratz & Mike Velings
4Alt. Nutrition FundsUS / EuropeFood-Tech (funds)VC and growth funds focused on alternative-protein solutions€1,000,000 + €500,000AUM €300M2021 onward—
5Algama FoodsFRFood-TechMicroalgae-based ingredients, including egg replacers€1,004,420€13M2,022Alvyn Severien
6EvodiaBioDKFood-Loss / Food-TechPrecision-fermented natural aromas and flavours; raised €6M in Dec 2025€960,365€6.4M (site)2,022Camilla Kloss Fenneberg
7CropXIL / USAgri-TechData-driven farm management and soil sensing; launched CropX Vision AI monitoring tool; first EBITDA-positive quarter expected Q2 2026€763,818$25M (Series C)Oct 2023Tomer Tzach
8Onego BioFIFood-TechAnimal-free egg white (ovalbumin) via precision fermentation; FDA approval reported for its Bioalbumen€750,000$40M2,024Maija Itkonen
9Standing OvationFRFood-TechAnimal-free casein via precision fermentation; R&D partnership with Bel Group; 7 patents in 3 families€750,000€30M (site); €46M equity plus €8M non-dilutive cumulative per deckQ1 2026Yvan Chardonnes
10YeastupCH (tech.eu lists BE)Food-TechProtein and fibre ingredients upcycled from brewer's spent yeast; first 40-hectolitre industrial unit launched€630,000€9.5M2,024Daniel Gnos
11Proteon PharmaceuticalsPLAgri-TechBacteriophage-based microbiome protection to combat antibiotic resistance in animals€600,275$25M2,021Prof. Jarosław Dastych
12Perfat TechnologiesFIFood-TechPatented oleogel fat alternatives; Newtree co-led the Sep 2025 Series A€600,000€2.5M (site); $2.93M Series A per CB InsightsSep 2025Jyrki Lee-Korhonen
13New School FoodsCAFood-TechWhole-cut plant-based salmon fillets using patented technology$600,000$12M2,023Chris Bryson
14OrbiskNLFood-LossAI and computer vision that measure and cut food waste in professional kitchens€500,000€3.5M (extension)2026 (date n/d)Anastasia Dellis
15Cubiq FoodsESFood-TechFat replacers for alternative proteins. Has filed for bankruptcy (OGM 2026).€500,000 (SAFE bridge)€5M2,022A. Montefeltro & Dr R. Revilla
16Agri Seed Fund (unnamed)USAgri-Tech (fund)Pre-seed to Series A agri-food tech VC$500,000Fund size $75–100M2,022—
17ForeverlandITFood-TechCocoa-free chocolate alternative ("Choruba") from fermented carob; claims price below €4/kg€350,000€6MMar 2026Massimo Sabatani
18UbeesFR / USAgri-TechPrecision beekeeping, hive leasing and biodiversity services; EBITDA-positive since 2024€344,000€8MQ4 2025 – Q1 2026Louis Delelis-Fanien
19Atomo CoffeeUSFood-LossBean-free upcycled coffee; pivoted toward prebiotic coffee€314,441$40M2,022Andy Kleitsch
20ProtixNLFood-Tech / Food-LossInsect ingredients for feed and food€299,879€40M2,021Kees Aarts & Tarique Arsiwalla
21Fable FoodsAUFood-Tech / Food-LossPlant-based meat from discarded shiitake mushrooms; entered Waitrose UK, reaching 1,500+ stores on three continents€284,495$10M2,022Michael Fox
22Clay Capital (fund)—FundsSector VC fund——2,024—
23Three sector VC funds (2025)—FundsFood-tech fundsn/d (part of €2.4M deployed in 2025)—2,025—
Country€ tickets (k)$ tickets (k)
Belgium2,2500
Spain2,2500
France2,0980
Netherlands2,0000
Finland1,3500
Denmark9600
Israel / US (CropX)7640
Switzerland6300
Poland6000
Italy3500
Australia2840
United States1,814500
Canada0600

Headline ticket sizes are as shown on Newtree Impact's portfolio pages and may be initial tickets or cumulative amounts. USD-denominated tickets are shown in USD. "Capital raised" is the investee's round or cumulative raise as stated by Newtree Impact.

Count reconciliation: the company reports 17 direct lines and 8 funds. The list above shows 18 named direct companies, including Orbisk, which was added after the deck, and Cubiq, which is now bankrupt. Fund lines are only partly named.

Summary of headline tickets by country (derived from the table; € and $ amounts shown separately, not converted).

Newtree Group consumer products (portfolio company)

Product lineDescriptionSpecifications / claimsPrice (where shown)ChannelSource
Chocolate bars (30g)Dark chocolate with speculoos; milk chocolate with almondsOrganic, Fairtrade, carbon-neutral, Belgian€29.95 per pack of 20 × 30gE-shop (free Belgian delivery from €50)newtree.com, accessed Oct 2026
"Delectable" gift boxBox of five Latin American origin chocolates, or a custom selectionSingle-origin positioning€23.90E-shopnewtree.com
Spreads (pâte à tartiner)Chocolate spreadsOrganic, vegetarian, ambient—E-shop; B2Bnewtree.com; food.be
Neapolitans and pralinesSmall chocolates, also sold as private label (e.g., for Exki)Organic—B2B in BE, DK, FR, ES, SE, UKfood.be
Newtree Coffee (office coffee)Sustainable coffee service for companies with free tasting offerOrganic, Fairtrade, CO2-neutral—B2B workplacenewtree.com; student.be job ad
Historical functional range (2005–2010s)80g bars with plant extracts (Eternity, Vivacity, Tranquility, Pleasure, Sexy, Young, Cocoon, Vigor, Renew, Rejoice, Forgiveness)73% cocoa dark; 30–33% milk; no preservatives, colourants or GMOs—Grocery, specialty, travel retailTrade press; USPTO trademark records
Historical organic rangeBelgian biscuit, cinnamon and ginger bars; waffle cookiesOrganic, Fairtrade, high-fibre—Grocery (EU, US)Snack & Bakery

Financial Narrative

Basis and limitations. Full audited income statements and balance sheets are publicly available for FY2024 and FY2025 only, in Belgian GAAP standalone format (OGM, 2 Jun 2026). For FY2021–FY2023 the company discloses NAV, the NAV bridge, opex and capital deployment, but not full accounts in the sources reviewed. Belgian GAAP books participations at cost less permanent write-downs, so unrealised gains appear only in NAV. Conventional operating metrics (gross margin, EBITDA margin, revenue CAGR, cash conversion cycle) are not meaningful for this business. They are shown blank or marked n/m (not meaningful) rather than invented.

Income statement

Notes: FY2024 year-end shares are taken as about 8.97M, implied by the Ecco Nova II pre-money of €23,330,512.40 at €2.60 per share. FY2025 year-end shares are 12,819,428. Weighted-average share counts and diluted EPS are not disclosed. Vendors report trailing EPS of −€0.21 (MarketInOut) and −$0.23 (PitchBook). The only earlier P&L datapoint in the sources is FY2020 (Craft): gross profit €58k, EBIT −€175k, net loss −€178k, cash €268k, when the business was still in transition. The P&L reconciles: FY2025 = −541 − 57 + 34 − 57 − 2,249 = −2,870 (rounding to −2,869); FY2024 = −466 − 44 + 95 − 5 − 1,470 = −1,890.

Margins. Gross, operating, EBITDA and net margins are not meaningful (n/m) with €5–32k of revenue. Revenue CAGR is also n/m.

Commentary. The FY2025 loss of €2.87M is almost entirely non-cash: €2.25M of write-downs on participations, of which the Cubiq Foods bankruptcy is a disclosed contributor, plus about €0.6M of costs. FY2024's €1.89M loss was likewise driven by €1.47M of write-downs. Cash costs rose 22% in FY2025 (€471k to €573k), mainly salaries (+30%), reflecting hires including Investment Analysts and a Head of Expansion & Impact. Interest income fell from €95k to €34k despite much higher cash at year-end. That points to the €10M raise landing very late in the year (December 2025) and to lower deposit rates. Interest expense rose to €57k even though there is no financial debt; the source is not explained (possibly bank or transaction charges).

NAV-based performance (the economically relevant P&L)

Source: OGM, 2 Jun 2026 (NAV evolution, bridge and key metrics). The year-end 2020 starting point was NAV €2.3M and €1.46 per share. As of 30 Apr 2026 (unaudited estimate) NAV was €26M, €2.01 per share, MOIC 0.87x total and 0.91x excluding funds. MOIC values were read from a chart, and their alignment to years is the analyst's best reading. The FY2024 capital raise of €6.8M combines the €5.4M and €1.4M items shown in the bridge (the March 2024 private placement plus the mid-2024 crowdlisting). Opex differs between the bridge and the key-metrics table for FY2021 (€0.2M versus €0.04M). The two disclosures are inconsistent, and the difference is not explained.

Commentary: the central inflection. NAV per share rose about 47% between end-2020 and end-2023 (€1.46 to €2.15) and then fell 8% over two years to €1.98. Portfolio MOIC fell from 1.14x to 0.84x. Absolute NAV kept growing only because new money came in (€16.8M raised in 2024–2025). The decline lines up with the 2023–2025 downturn in alternative-protein funding: global agri-food tech VC fell from $56.6B (2021) to about $16B a year (2023–2025), according to AgFunder data cited in the deck. That downturn forced down-rounds and failures, including Cubiq. A recovery to €2.01 per share by April 2026 hints at stabilisation. The €2.90 (2024) and €2.60 (2025) issue prices were set well above the NAV per share at the time (€2.09 and €1.98). New investors therefore paid a premium that diluted NAV per share upward for existing holders, and those new investors are currently under water on a NAV basis.

Balance sheet

Notes: The company states the holding has no financial debt, or virtually none. The book value of participations (€13.7M) is below cumulative capital invested (€17.5M) because write-downs are booked while gains are not. NAV (€25.4M) exceeds book equity (€24.4M) by about €1.0M, which is the net unrealised uplift recognised under IPEV but not under Belgian GAAP. Disclosures of the invested amount vary: €17.5M (financial summary), €17.9M (2025 highlights) and €19M (2026 "at a glance", presumably after the Q1 2026 deals).

Cash flow (proxies)

No statutory cash-flow statement is published in the sources. The figures below are management-basis proxies taken from the NAV bridge and investment-pace disclosures.

Commentary: Cash rose €7.2M in FY2025 because €10M was raised while only €2.4M was deployed. The holding enters 2026 with roughly 18 years of opex covered by cash at the current run-rate, or about four to five years of deployment at the 2021–2025 average pace of €3.1M a year. Q1 2026 commitments of €1.1M (Standing Ovation and Foreverland), the Orbisk ticket (€0.5M) and follow-ons in Yeastup and New School Foods mean cash at mid-2026 is likely lower than at year-end. The exact figure is not disclosed.

Ratios (FY2024–FY2025)

Not meaningful or not computable: ROIC, net debt/EBITDA (net cash with negative EBITDA), interest coverage (negative EBIT), asset turnover and cash conversion cycle. NAV total return per share is derived as the change in NAV per share (for example FY2021 = 1.58 / 1.46 − 1). The derived FY2024 ROE of −10.9% matches MarketInOut's −10.84%.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRoleRelationshipStatus

NEWTREE SA (Newtree Impact)

Listed investment holding

Parent / issuer

Active; Euronext Access Brussels

Newtree Group SA

Chocolate and coffee brand ("Newtree"); office-coffee service ("Newtree Coffee")

Portfolio participation; described as a spin-off. About €2.25M headline commitment, approved end-2023 and executed in tranches, with €200k invested in 2025.

Active; CEO Jean-François Cambier (from 2025)

Newtree SARL (Lyon)

Historical French distribution affiliate (2002)

Historical affiliate

Current status not publicly disclosed

US entities (San Francisco; Grand Haven, MI)

Historical US chocolate operations and café

Historical

Current status not publicly disclosed

Theme Details

ThemeContents% of capital invested FY2025Derived € (M) on €17.5M invested

Food-Tech

Alternative proteins, fermentation, alternative fats and cocoa, plant-based foods, insect ingredients, Newtree Group

7613.3

Agri-Tech

Precision agriculture (CropX), pollination (Ubees), aquaculture (Aqua-Spark), animal health (Proteon), agri seed fund

244.2

Theme Details (Projected NAV contribution 2025→2032 (EUR Mn))

ThemeProjected NAV contribution 2025→2032 (EUR Mn)

Starting NAV (31 Dec 2025)

25.4

Food-Tech uplift

27.0

Agri-Tech uplift

4.9

Funds uplift

2.2

Projected NAV 2032

59.5

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (EUR K)

———532

Operating expenses (EUR K)

———-471-573

of which salaries (EUR K)

———-355-462

of which office rent and supplies (EUR K)

———-26-28

of which other expenses (EUR K)

———-81-74

of which listing fees (EUR K)

———-9-9

EBITDA, operating profit before D&A (EUR K)

———-466-541

Depreciation and amortisation (EUR K)

———-44-57

Operating income / EBIT, derived (EUR K)

———-510-598

Interest income (EUR K)

———9534

Interest expense (EUR K)

———-5-57

Value reductions on participations (EUR K)

———-1,470-2,249

Pre-tax income (EUR K)

———-1,890-2,869

Net income (EUR K)

———-1,890-2,869

EPS basic, derived on year-end shares (EUR)

———-0.21-0.22

Dividends per share (EUR)

00000

Key Financials and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

NAV, year-end (EUR Mn)

4.68.913.918.825.4

NAV per share (EUR)

1.581.912.152.091.98

Capital raised in year (EUR Mn)

2.44.14.36.810.0

Portfolio revaluations (EUR Mn)

0.10.31.0-1.4-2.8

Opex per NAV bridge (EUR Mn)

-0.2-0.2-0.3-0.5-0.6

Opex per key-metrics table (EUR Mn)

0.040.180.290.420.60

Opex / NAV (%)

0.82.12.12.22.3

MOIC, total portfolio (x)

1.031.061.141.000.84

MOIC excluding funds (x)

1.000.991.111.060.85

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (EUR K)

———17,37524,763

Cash and cash equivalents (EUR K)

———3,61510,779

Receivables (EUR K)

———5983

Total current assets (EUR K)

———3,68510,867

Financial fixed assets, participations at book (EUR K)

———13,57413,734

Formation / establishment costs (EUR K)

———108158

Intangible assets (EUR K)

———32

Tangible assets (EUR K)

———52

Short-term debt (EUR K)

———00

Long-term debt (EUR K)

———00

Total debt (EUR K)

———00

Net debt (EUR K)

———-3,615-10,779

Total current liabilities (EUR K)

———99357

Paid-in capital (EUR K)

———19,84129,841

Retained losses brought forward (EUR K)

———-692-2,583

Shareholders' equity, book (EUR K)

———17,27524,406

Goodwill and intangibles (EUR K)

———32

Working capital, derived (EUR K)

———3,58610,510

Cumulative capital invested, management basis (EUR Mn)

4.07.610.715.017.5

Balance Sheet — Cash opex proxy, from P&L

MetricFY2021FY2022FY2023FY2024FY2025

Cash opex proxy, from P&L (EUR K)

———-471-573

Capital deployed into investments (EUR Mn)

2.03.73.14.32.4

Equity raised (EUR Mn)

2.44.14.36.810.0

Dividends paid (EUR K)

00000

Share buybacks (EUR K)

00000

Change in cash (EUR K)

————7,164

Margin Analysis (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE on year-end book equity (%)

———-10.9-11.8

ROA on year-end assets (%)

———-10.9-11.6

NAV total return per share (%)

8.220.912.6-2.8-5.3

Current ratio (x)

———37.230.4

Debt / equity (x)

———00

Cash / NAV (%)

———19.242.4

Opex / NAV (%)

0.82.12.12.22.3

Region Overview

RegionDirect-ticket sum (k, mixed €/$ at face value)Share of total (%)

Europe (BE, ES, FR, NL, FI, DK, CH, PL, IT)

12,48875

North America (US, CA)

2,91418

Middle East (Israel, CropX)

7645

Asia-Pacific (Australia, Fable)

2842

Share Price & Returns

PeriodReturn (%)Source

1 month

-2.50

Zonebourse, 16 Oct 2026

3 months

-2.50

Zonebourse

6 months

-2.50

Zonebourse

Year to date 2026

-18.75

Zonebourse

1 year

-24.42

Zonebourse

3 years

2.63

Zonebourse

5 years

21.88

Zonebourse

10 years

95.00

Zonebourse

Margin Analysis (%) and Share Price

MetricFY2021FY2022FY2023FY2024FY2025

Calendar-year share return (%)

250.00-28.5712.0064.294.35

Year-end share price, derived (EUR)

1.751.251.402.302.40

Year-end NAV per share (EUR)

1.581.912.152.091.98

Price / NAV at year-end, derived (x)

1.110.650.651.101.21

Capital Markets Data and Operating Metrics (shares)

MetricFY2024FY2025

Trading value (EUR K)

116357

Volume (thousand shares)

47150

Average daily volume (shares)

445587

Valuation Multiples

MultipleNewtree ImpactBasis

Market cap (EUR Mn)

25.0

12,819,428 × €1.95

Price / NAV (x)

0.98

€1.95 / €1.98 (Dec 2025)

Price / book (x)

1.02

€25.0M / €24.4M book equity

Enterprise value (EUR Mn)

14.2

Market cap minus €10.8M cash (Dec 2025); likely understated because cash has since been deployed

P/E

n/m

Negative earnings

EV/EBITDA

n/m

Negative EBITDA

EV/Sales

n/m

Negligible revenue

Analyst Conclusions

Management guidance and targets

The company issues no earnings guidance. Its forward-looking statements are: target IRR of 12–15%; a projected NAV of €59.5M by 2032 with no new capital (2.3x, 12.6% IRR); EBITDA breakeven milestones at Heura (achieved Q1 2026), Fable (Q2 2026), Ubees (Q2 2026) and CropX (Q2 2026 quarter, full year 2027); growth to €50–100M of equity and 35–40 holdings; and an upcoming capital increase. There is no consensus, as the stock has no analyst coverage.

Bull case

  1. Valuation trough plus dry powder. With €10.8M of cash (42% of NAV) deployable after agri-food VC funding fell 71% from its 2021 peak, the 2025–2026 vintages (Perfat, Ubees, Standing Ovation, Foreverland, Orbisk) were bought at reset prices. The April 2026 NAV uptick to €2.01 may mark the turn.

  2. Portfolio inflecting to profitability. Four holdings are EBITDA-positive or about to be. Heura is the largest direct food-tech line at €1.75M. That improves write-up potential and the odds of exits within three to five years.

  3. Structural cost advantage and institutional anchors. About 2% opex with no fees or carry, together with WE and SFPIM on the register, gives a credible platform to scale toward €50–100M, which would dilute fixed costs and support a NAV premium.

Bear case

  1. Value destruction is still unfolding. NAV per share has fallen two years running. Portfolio MOIC is 0.84x after about six years, and 47% of direct lines are early-stage or pre-revenue. Cubiq's bankruptcy may not be the last.

  2. Investors paying above NAV. Raising at €2.90 and €2.60 against NAV of €2.09 and €1.98 per share flatters existing holders but leaves recent investors under water. If that becomes visible, future raises, which the model depends on, could stall.

  3. Illiquidity and structure. A tiny float on Euronext Access, no exits, no distributions and an unregulated holding wrapper mean shareholders may find it hard to realise value even if NAV rises.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhat to watch
Investor meeting26 Nov 2026H1 2026 NAV, cash position, raise terms
Next capital increaseLate 2026 / 2027Size, price versus NAV, institutional participation
Board renewal outcomePost-June 2026Names and independence of the two nominees
Portfolio EBITDA milestonesQ2 2026 onwardConfirmation at Fable, CropX, Ubees
Further insolvencies or write-downsOngoingEarly-stage lines (Algama, Atomo, New School, Perfat)
First exitUnscheduledAny realised gain would validate NAV marks
Newtree Group performanceFY2026Revenue and margin under the new CEO; cocoa cost pass-through
FY2026 audited NAV~Jun 2027 OGMNAV per share trend versus €1.98
Secondary liquidity programme2026–2027Mechanism and pricing

Analyst verdict

Newtree SA is no longer a chocolate company. It is a €25M listed impact-venture holding whose shares trade at roughly NAV (0.98x) on almost no volume. The conversion has been well executed in governance and capital-raising terms. About €30M has been raised from more than 750 holders, two public-sector institutions have anchored the latest round, costs are about 2% of NAV with no carry, and the société-à-mission framework with IRIS+ reporting is ahead of most impact peers in its niche.

The financial record is weaker. Since the 2023 peak, NAV per share has fallen from €2.15 to €1.98, and the portfolio's aggregate MOIC has dropped below 1x (0.84x at end-2025). Belgian GAAP losses widened to €2.9M in FY2025 on €2.25M of write-downs, including the first outright failure (Cubiq). Without exits, the €59.5M NAV projection for 2032 cannot yet be tested. Repeated issuance above NAV has protected NAV per share for existing holders but has priced new money expensively.

The investment question therefore comes down to whether the portfolio will mature. There are positive signals: Heura and Ubees are EBITDA-positive, Onego Bio has FDA approval, Standing Ovation has raised capital alongside Bel and Danone, and the April 2026 NAV estimate ticked up. The company also has unusually high cash (about 42% of NAV at year-end) to deploy at reset valuations. Against that, it has a very thin float, a five-person team, a founder-CEO who has led the company for 25 years, sub-scale tickets and heavy reliance on future capital raises.

For an investor seeking diversified, low-fee, mission-aligned exposure to agri-food technology, and able to hold for a decade without needing liquidity, buying at or below NAV is a defensible entry. For anyone needing liquidity, evidence of realised returns or institutional-grade disclosure, the stock remains speculative. The key tests over the next 12 months are the terms of the next capital raise, the H1 2026 NAV and any first exit.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / notesPrior roles / educationAgeCompensation

Benoît de Bruyn

Founder & CEO

Board member since 29 Mar 2001; CEO tenure recorded from 31 May 2010

Founder of NewTree chocolate (2001); chemical engineer by training

About 56, derived from "35 years old" in 2005 press

Not individually disclosed

Jean-Nicolas Fassin

Secretary General

————

Nathalie Peeters

Head of Expansion & Impact

————

Thibaud de Saint-Quentin

Portfolio Advisor; sits on Board and Investment Committee

Board since 31 May 2010 per vendor data

———

Lisa Colombo

Investment Analyst

————

Abhishek Anand

Investment Analyst

————

Investment Manager

Vacant (recruitment advertised)

2,026

Profile sought: 7–10 years of agri-food / bioeconomy investing

——

Jean-François Cambier

Operating Partner; CEO of Newtree Group SA

Hired 2025

———

Board of Directors

NameRoleSinceNotes

Bruno Colmant

Chairman

—

Belgian economist; opened the June 2026 OGM as Chairman

Michael Baum

Director

—

Also listed as investor and board member (Caplight)

Frédéric Pouchain

Director

——

Raymond Vaxelaire

Director

Jan 2007 (recorded 05/01/2007)

Independent non-executive per MarketScreener

Emilie Dallemagne

Director

——

Udaiyan Jatar

Director

1 Jun 2011

Long-standing director from the chocolate era

Board Committees

CommitteeMembersRole

Investment Committee

Serge Demoulin, Fabian Seunier, Nicolas Saillez, Antoine Duchateau, Alain Balthazart (plus T. de Saint-Quentin as portfolio advisor)

Reviews investment decisions

Mission Committee

Etienne de Callataÿ (economist; joined 2025), Mathilde Do Chi (regulatory expert), Valentine Papeians (ESG in food), Hugues de Meulemeester (environmental expert)

Oversees the company's mission and impact commitments under its "société à mission" status

Board & Management Changes

DateChangeContext
2025

Jean-François Cambier appointed Operating Partner and CEO of Newtree Group SA

Separates management of the chocolate brand from the holding's CEO

2025

Etienne de Callataÿ joins Mission Committee

Strengthens economic and impact oversight

2026

Investment Manager recruitment

Team extension listed as a 2026 objective

2 Jun 2026

Two board nominations proposed

Outcome not disclosed

Major Shareholders

Holder (as named)Indicative stake (%)

Float

10

Founders

4

SFPIM (Belgian federal investment company)

6

Wallonie Entreprendre (Walloon regional investment agency)

8

Whitestone Group

12

Spinnova

10

Noshaq (Liège investment fund)

13

Other nominative (registered) shareholders

51

Competitive Landscape

Key Competitors

CompetitorTypeArenaRelative positioning vs Newtree Impact

Astanor Ventures (Brussels)

Agri-food tech VC (co-investor in a portfolio round)

Deal allocation

Far larger fund; a Brussels peer in the same niche; institutional rather than retail

PINC (Paulig)

Corporate VC

Deal allocation

Strategic investor; co-invested in Newtree deals twice

Big Idea Ventures

Alt-protein VC

Deal allocation

Global alt-protein specialist; co-investor in Perfat

Beyond Impact

Impact VC

Deal allocation

Co-led Perfat

European Circular Bioeconomy Fund (ECBF)

Thematic VC

Deal allocation

Larger dedicated bioeconomy fund

Danone Ventures / Bel Group

Corporate VC / strategics

Deal allocation

Strategic capital with commercial synergies Newtree cannot offer

Good Startup, Hatch, Peakbridge, Five Seasons Ventures, Blue Horizon

Food-tech VCs

Deal allocation

Specialist funds of varying size

Quest for Growth (Euronext Brussels)

Listed closed-end VC / growth fund

Investor capital

Longer-listed Belgian retail-accessible VC vehicle with broader tech focus and a regulated status

Gimv (Euronext Brussels)

Listed private-equity investor

Investor capital

Much larger, diversified, dividend-paying

Sofina (Euronext Brussels)

Listed investment holding

Investor capital

Global growth-equity holding at multi-billion scale

Crowdfunding platforms' direct deals (Spreds, Ecco Nova)

Retail co-investment

Investor capital

Single-company retail exposure versus Newtree's diversified wrapper

Competitor Detail

MetricNewtree Impact

NAV or AUM, latest (EUR Mn)

25.4

NAV per share growth, last FY (%)

-5.3

Opex / NAV (%)

2.3

Number of portfolio lines

25

Agri-food focus (% of capital)

100

Company Snapshot

5

Employees

2001

Founded

SWOT Analysis

Strengths

  • Debt-free balance sheet with large cash buffer: €10.78M cash, zero financial debt, current ratio 30.4x (FY2025 accounts).
  • Low cost structure: opex of €0.60M, equal to 2.3% of NAV, with no management fee or carry (OGM 2026 key metrics and term sheet).
  • Institutional validation: Wallonie Entreprendre and SFPIM anchored €8.7M of the December 2025 raise (WE, 22 Dec 2025).
  • Capital-raising track record: about €30M raised in roughly five years from more than 750 shareholders, including €16.8M in 2024–2025 (OGM 2026).
  • Portfolio maturing toward profitability: Heura EBITDA+ in Q1 2026; Ubees EBITDA+ since 2024; Fable and CropX targeting positive EBITDA in Q2 2026 (OGM 2026).
  • Quality co-investor syndicates: Bel Group, Danone Ventures and Bpifrance in Standing Ovation; Cargill, ECBF and EIFO in other rounds (tech.eu; press).
  • Distinctive governance: described as the first Belgian financial company with société à mission status, with an independent Mission Committee and IRIS+ impact reporting (company and LinkedIn statements).

Weaknesses

  • NAV per share falling: €2.15 (2023) to €2.09 (2024) to €1.98 (2025), and portfolio MOIC from 1.14x to 0.84x (OGM 2026).
  • Recurring accounting losses: net losses of €1.89M (FY2024) and €2.87M (FY2025), driven by €1.47M and €2.25M of write-downs.
  • No exits in about six years of investing; returns are entirely unrealised.
  • Sub-scale tickets: a median direct ticket of roughly €0.6M limits influence and information rights.
  • Illiquid stock: only €357k traded in all of FY2025; a €5k trade moved the price 18% (OGM 2026).
  • Inconsistent disclosures: invested capital shown as €17.5M, €17.9M and €19M; opex differs between tables; round labels conflict with external sources.
  • Key-person risk: founder-CEO since 2001, with a five-person team.

Opportunities

  • Deploying €10.8M of cash at reset valuations after the 2023–2025 trough in agri-food VC ($16.3B in 2025 versus $56.6B in 2021, per AgFunder).
  • Regulatory approvals (Onego Bio FDA) opening large US ingredient markets.
  • Cocoa supply volatility creating demand for alternatives (Foreverland at price parity, below €4/kg).
  • Belgian institutional co-investment pipeline following the entry of WE and SFPIM.
  • Secondary-liquidity programme and a planned capital raise that could deepen the float and support a NAV premium.
  • Exit potential from scaled assets such as Heura, Protix, CropX and Aqua-Spark.
  • Projected NAV of €59.5M by 2032 if the portfolio performs (management projection, 12.6% IRR).

Threats

  • Further portfolio failures: Cubiq is already bankrupt; 47% of direct participations are either early-stage (35%) or pre-revenue (12%).
  • Alternative-protein demand weakness hurting valuations (Fable, New School, Heura).
  • Harder future raises: Ecco Nova explicitly flags the risk that further capital increases become harder, threatening the model.
  • Issue prices above NAV (€2.60 versus €1.98 NAV per share), which may deter new investors as information spreads.
  • Regulatory risk: the "holding, not fund" positioning could be challenged under AIFMD or by the FSMA.
  • Currency exposure on USD tickets (New School, Agri Seed Fund, US funds).
  • Commodity-price risk at Newtree Group, its largest direct line (€2.25M), from cocoa volatility.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
2025 (date n/d)Jean-François Cambier hired as Operating Partner and CEO of Newtree Group SAProfessionalises the consumer spin-off and frees founder bandwidth
2025 (date n/d)Etienne de Callataÿ joins the Mission CommitteeAdds governance weight to the impact framework
2025 (date n/d)First Annual Impact Report (2025 edition) published, using IRIS+ and planetary boundariesDifferentiates against generic ESG claims
2025Seven follow-ons: Newtree Group, Proteon, Algama, Protix, Aqua-Spark, Yeastup, EvodiaBioSupports existing portfolio but concentrates risk
2025Commitments to three sector VC fundsRaises fund exposure toward 27% of capital
10–11 Sep 2025Co-leads Perfat Technologies Series A ($2.93M) with Beyond ImpactFirst lead role in a Finnish deal
Dec 2025EvodiaBio secures €6MPositive financing signal for a 2022 holding
19 Dec 2025Private placement documentation publishedFormalises the €10M raise
20–22 Dec 2025€10M capital increase announced (L'Echo, Trends, WE) at €2.60 per shareLargest raise in company history; NAV-accretive because priced above NAV
Dec 2025First BE–FR cross-border crowdlisting raises €1.3M from 295 investorsBroadens the retail base to more than 750 shareholders
31 Dec 2025NAV €25.4M; NAV per share €1.98 (down from €2.09); FY2025 net loss €2.87M with €2.25M of write-downsSecond consecutive year of NAV-per-share decline
Q4 2025 – 6 Feb 2026Invests €344k in Ubees (€8M round)Agri-tech diversification into an already EBITDA-positive company
Q1 2026Heura Foods reaches positive EBITDALargest direct food-tech line (€1.75M) de-risks
Q1 2026Shortlisted among the top 30 nominees for the L'Echo / De Tijd Changemakers AwardReputational
Q1 2026Mission Committee session on asset classes; 2025 Mission Report releasedGovernance
Q1 2026Follow-ons in Yeastup and New School FoodsContinued support of 2023–2024 vintages
Early 2026 (date n/d)Share falls from €2.44 to €2.00 (−18%) in four days on just 2,378 shares (€5,011)Shows extreme price sensitivity to a thin float
24–25 Mar 2026€350k in Foreverland's €6M roundCocoa-alternative bet; synergy with the chocolate heritage
31 Mar 2026Standing Ovation round with Bel Group and Danone Ventures; Newtree €750kTies into a strategic syndicate
21 Apr 2026Standing Ovation's raise reported at $34.2MValidates a precision-fermentation dairy holding
30 Apr 2026Estimated NAV per share €2.01, NAV €26M (unaudited)First uptick after two years of decline
H1 2026 (date n/d)Cubiq Foods files for bankruptcyFirst portfolio failure (€0.5M SAFE)
H1 2026 (date n/d)Onego Bio receives FDA approval for BioalbumenRegulatory de-risking for a 2024 holding
H1 2026 (date n/d)Fable Foods enters Waitrose UK (1,500+ stores on three continents)Commercial traction
H1 2026 (date n/d)CropX launches CropX Vision AI tool; Yeastup opens its first 40 hl industrial facility; Atomo pivots to prebiotic coffeeMixed portfolio execution signals
2 Jun 2026OGM approves FY2025 accounts; two board nominations proposed; another capital increase flaggedGovernance and funding pipeline
2026 (date n/d)€500k investment in Orbisk (€3.5M extension)Food-loss diversification
2026Investment Manager role advertised (ImpactAlpha)Team build-out
16 Oct 2026Share at €1.95; YTD −18.75%; 1-year −24.4%; near-zero daily volumesTrading slightly below last reported NAV per share
26 Nov 2026 (upcoming)Annual investor meetingLikely venue for the H1 NAV update and new raise

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Income Statement: Revenue & Gross Profit: Revenue rose from EUR 0 Mn in FY2024 to EUR 0 Mn in FY2025.
Newtree S.A. — Income Statement: Revenue & Gross Profit
Series (EUR Mn)FY2024FY2025
Revenue00

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Euronext / Mondo Visione, "Listing of NewTree S.A. on Euronext", 12 Dec 2005 (mondovisione.com)
  2. Newtree Impact, Ordinary General Meeting presentation including FY2025 audited accounts, 2 Jun 2026 (newtreeimpact.com)
  3. Newtree Impact website, home page (newtreeimpact.com)
  4. Newtree Impact website, Investors page (newtreeimpact.com)
  5. Newtree Impact website, Portfolio pages 1–3 (newtreeimpact.com)
  6. Newtree (Newtree Group brand) website (newtree.com)
  7. Zonebourse, NewTree SA quotes and performance (accessed Oct 2026) (zonebourse.com)
  8. Zonebourse, NewTree SA company profile and governance (zonebourse.com)
  9. Wallonie Entreprendre, "Newtree Impact lève 10 millions…", 22 Dec 2025 (wallonie-entreprendre.be)
  10. Spreds, Newtree Impact 1A offer and financials: and: spreds.com · spreds.com
  11. Spreds, Newtree Impact II offer (spreds.com)
  12. Ecco Nova, Newtree Impact offer (2024) (ecconova.com)
  13. Ecco Nova, Newtree Impact II offer (2025) (ecconova.com)
  14. BDO Belgium, Newtree Impact deal case study (bdo.be)
  15. Silicon Canals, "Newtree Impact backs CropX Technologies", Oct 2023 (siliconcanals.com)
  16. CB Insights, Newtree Impact investor profile (cbinsights.com)
  17. tech.eu funding database, NewTree Impact (funding.tech.eu)
  18. Caplight, Newtree Impact profile (caplight.com)
  19. Tracxn, Newtree Impact profile (tracxn.com)
  20. ImpactAlpha, Newtree Impact Investment Manager job listing (impactalpha.com)
  21. PitchBook, Newtree Group profile preview (pitchbook.com)
  22. MarketInOut, NewTree S.A. profile (marketinout.com)
  23. Craft, NewTree profile (craft.co)
  24. MarketScreener, Raymond Vaxelaire insider profile (in.marketscreener.com)
  25. Food4Media, NewTree press release, Nov 2005 (food4media.com)
  26. FoodIngredientsFirst, "NewTree creates unique range of chocolate", 23 Nov 2005 (foodingredientsfirst.com)
  27. SG Network, "New Tree plans push in the UK market", Jul 2006 (sg-network.org)
  28. NutritionInsight, NewTree / Barry Callebaut products, Jan 2008 (nutritioninsight.com)
  29. Moodie Davitt Report, NewTree travel retail appointment, Feb 2009 (moodiedavittreport.com)
  30. Candy Industry, New Tree San Francisco store, May 2012 (candyindustry.com)
  31. Justia Trademarks, NewTree SA trademarks (trademarks.justia.com)
  32. food.be, Newtree B2B listing (food.be)
  33. ConfectioneryNews, Commodities coverage (cocoa prices 2026) (confectionerynews.com)
  34. LinkedIn, Jean-François Cambier activity (Changemakers nomination; société à mission) (be.linkedin.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.